The results are from the prospective, multicenter, phase 3 explorer7 trial, involving 133 patients, including 80 with hemophilia A and 53 had hemophilia B.
Prophylactic concizumab conferred significant reductions in treated spontaneous and traumatic bleeds among patients with hemophilia A or B without inhibitors, a primary analysis of the randomized phase 3 explorer8 study showed.Concizumab (Novo Nordisk) prophylaxis reduced the number of bleeds by 86% for trial participants with hemophilia A and by 79% for participants with hemophilia B compared